These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36228755)

  • 41. Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers.
    Zhou QT; Qu L; Gengenbach T; Larson I; Stewart PJ; Morton DA
    AAPS PharmSciTech; 2013 Mar; 14(1):38-44. PubMed ID: 23196863
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
    Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
    Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterisation and functionality of inhalation anhydrous lactose.
    Pitchayajittipong C; Price R; Shur J; Kaerger JS; Edge S
    Int J Pharm; 2010 May; 390(2):134-41. PubMed ID: 20100552
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection.
    Rashid MA; Muneer S; Mendhi J; Sabuj MZR; Alhamhoom Y; Xiao Y; Wang T; Izake EL; Islam N
    Int J Pharm; 2021 Oct; 608():121122. PubMed ID: 34560207
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhalable lactose-based dry powder formulations of low molecular weight heparin.
    Bai S; Gupta V; Ahsan F
    J Aerosol Med Pulm Drug Deliv; 2010 Apr; 23(2):97-104. PubMed ID: 19778265
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of budesonide nanocluster dry powder aerosols: preformulation.
    El-Gendy N; Selvam P; Soni P; Berkland C
    J Pharm Sci; 2012 Sep; 101(9):3434-44. PubMed ID: 22623018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Continuous twin screw extrusion for the wet granulation of lactose.
    Keleb EI; Vermeire A; Vervaet C; Remon JP
    Int J Pharm; 2002 Jun; 239(1-2):69-80. PubMed ID: 12052692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Relationship Between the Permeability and the Performance of Carrier-Based Dry Powder Inhalation Mixtures: New Insights and Practical Guidance.
    Shalash AO; Khalafallah NM; Molokhia AM; Elsayed MMA
    AAPS PharmSciTech; 2018 Feb; 19(2):912-922. PubMed ID: 29063377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization,
    Acosta MF; Muralidharan P; Grijalva CL; Abrahamson MD; Hayes D; Fineman JR; Black SM; Mansour HM
    Ther Adv Respir Dis; 2021; 15():1753466621998245. PubMed ID: 33719747
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a Rational Design Space for Optimizing Mixing Conditions for Formation of Adhesive Mixtures for Dry-Powder Inhaler Formulations.
    Sarkar S; Minatovicz B; Thalberg K; Chaudhuri B
    J Pharm Sci; 2017 Jan; 106(1):129-139. PubMed ID: 27546350
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of budesonide nanocluster dry powder aerosols: formulation and stability.
    El-Gendy N; Huang S; Selvam P; Soni P; Berkland C
    J Pharm Sci; 2012 Sep; 101(9):3445-55. PubMed ID: 22619045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of budesonide nanocluster dry powder aerosols: processing.
    El-Gendy N; Selvam P; Soni P; Berkland C
    J Pharm Sci; 2012 Sep; 101(9):3425-33. PubMed ID: 22539360
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Linking granulation performance with residence time and granulation liquid distributions in twin-screw granulation: An experimental investigation.
    Kumar A; Alakarjula M; Vanhoorne V; Toiviainen M; De Leersnyder F; Vercruysse J; Juuti M; Ketolainen J; Vervaet C; Remon JP; Gernaey KV; De Beer T; Nopens I
    Eur J Pharm Sci; 2016 Jul; 90():25-37. PubMed ID: 26709082
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Co-electrospraying technology as a novel approach for dry powder inhalation formulation of montelukast and budesonide for pulmonary co-delivery.
    Yaqoubi S; Adibkia K; Nokhodchi A; Emami S; Alizadeh AA; Hamishehkar H; Barzegar-Jalali M
    Int J Pharm; 2020 Dec; 591():119970. PubMed ID: 33059013
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Visualization and understanding of the granulation liquid mixing and distribution during continuous twin screw granulation using NIR chemical imaging.
    Vercruysse J; Toiviainen M; Fonteyne M; Helkimo N; Ketolainen J; Juuti M; Delaet U; Van Assche I; Remon JP; Vervaet C; De Beer T
    Eur J Pharm Biopharm; 2014 Apr; 86(3):383-92. PubMed ID: 24211658
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics.
    Begat P; Morton DA; Staniforth JN; Price R
    Pharm Res; 2004 Oct; 21(10):1826-33. PubMed ID: 15553229
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Air classifier technology (ACT) in dry powder inhalation. Part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2003 Jul; 260(2):187-200. PubMed ID: 12842339
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The influence of operational parameters and feed preparation in a convective batch ribbon powder mixer.
    Yeow ST; Shahar A; Abdul Aziz N; Anuar MS; Yusof YA; Taip FS
    Drug Des Devel Ther; 2011; 5():465-9. PubMed ID: 22162640
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Controlled Pulmonary Delivery of Carrier-Free Budesonide Dry Powder by Atomic Layer Deposition.
    La Zara D; Sun F; Zhang F; Franek F; Balogh Sivars K; Horndahl J; Bates S; Brännström M; Ewing P; Quayle MJ; Petersson G; Folestad S; van Ommen JR
    ACS Nano; 2021 Apr; 15(4):6684-6698. PubMed ID: 33769805
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats.
    Carvalho SR; Watts AB; Peters JI; Liu S; Hengsawas S; Escotet-Espinoza MS; Williams RO
    Eur J Pharm Biopharm; 2014 Sep; 88(1):136-47. PubMed ID: 24859653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.